3-ethoxycarbonyl-5-(o-hydroxybenzoyl)-1-(furan-2-yl-methyl)pyridin-2-one | 1432594-78-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-ethoxycarbonyl-5-(o-hydroxybenzoyl)-1-(furan-2-yl-methyl)pyridin-2-one
• 英文别名: Ethyl 1-(furan-2-ylmethyl)-5-(2-hydroxybenzoyl)-2-oxopyridine-3-carboxylate；ethyl 1-(furan-2-ylmethyl)-5-(2-hydroxybenzoyl)-2-oxopyridine-3-carboxylate
• CAS: 1432594-78-9
• 化学式: C₂₀H₁₇NO₆
• 分子量: 367.358
• InChiKey: BAXMESBGFZYFMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  97
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-呋喃甲胺 、 在 cesium fluoride 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以95%的产率得到3-ethoxycarbonyl-5-(o-hydroxybenzoyl)-1-(furan-2-yl-methyl)pyridin-2-one
  参考文献：
  名称：

  A versatile domino process for the synthesis of substituted 3-aminomethylene-chromanones and 2-pyridones catalyzed by CsF

  摘要：

  The addition of various primary amines onto 3-alpha,beta-unsaturated diester chromone derivative was studied under mild conditions. Basically, this reaction provided 2-pyridone-based compounds through an interesting domino 'Addition/Ring Opening/Ring Closure' process (ARORC). In this study, aniline and tryptamine series exhibited different reactivity profiles leading unexpectedly to 3-aminomethylene chromanones with or without the 2-pyridone derivatives. This constitutes the first description and study of 3-aminomethylene chromanone formation that is supposed to follow a domino process combining 'Addition/Ring Opening/Ring Closure by Oxa-Michael addition' (ARORCOM). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.03.096

文献信息

• [EN] COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR INHIBER LES VOIES EMT POUR TRAITER LE CANCER, LA FIBROSE D'ORGANE ET LES TROUBLES MÉTABOLIQUES
  申请人：UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION

  公开号：WO2018156459A1

  公开（公告）日：2018-08-30

  A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I: wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl; R1 is hydrogen, alkoxy, or substituted alkoxy; R2 is hydrogen, alkyl, or substituted alkyl; and R3 is hydrogen, alkyl, or substituted alkyl.

  化合物，或其药用可接受的盐或异构体，其化学式为I：其中R为氢、烷基、取代烷基、烯基或取代烯基；R1为氢、烷氧基或取代烷氧基；R2为氢、烷基或取代烷基；R3为氢、烷基或取代烷基。
• Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders
  申请人：University of Pittsburgh—Of the Commonwealth System of Higher Education

  公开号：US11078159B2

  公开（公告）日：2021-08-03

  A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I: wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl; R1 is hydrogen, alkoxy, or substituted alkoxy; R2 is hydrogen, alkyl, or substituted alkyl; and R3 is hydrogen, alkyl, or substituted alkyl.

  式 I 的化合物或其药学上可接受的盐或异构体： 其中 R 是氢、烷基、取代烷基、烯基或取代烯基； R1 是氢、烷氧基或取代的烷氧基 R2 是氢、烷基或取代烷基；和 R3 是氢、烷基或取代的烷基。
• COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20220017466A1

  公开（公告）日：2022-01-20

  A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I: wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl; R 1 is hydrogen, alkoxy, or substituted alkoxy; R 2 is hydrogen, alkyl, or substituted alkyl; and R 3 is hydrogen, alkyl, or substituted alkyl.